This report provides exclusive insights into the COVID-19 impact on the Benign Prostatic Hyperplasia Treatment Market. The detailed analysis provides information about the impact of the outbreak on the demand and supply conditions, trends and forecasts of the Benign Prostatic Hyperplasia Treatment Market. Moreover, the impact analysis covers the study of the COVID-19 on the supply chain of Benign Prostatic Hyperplasia Treatment Market. The sectoral impact shall provide insights into both short term and long term effects of the pandemic on the related and support industries.
A recent report published by Infinium Global Research on the benign
prostatic hyperplasia treatment market provides an in-depth analysis of segments
and sub-segments in the global as well as regional benign prostatic hyperplasia
treatment market. The study also highlights the impact of drivers, restraints,
and macro indicators on the global and regional benign prostatic hyperplasia
treatment market over the short term as well as long term. The report is a
comprehensive presentation of trends, forecast and dollar values of global benign
prostatic hyperplasia treatment market. According to the report, the global benign
prostatic hyperplasia treatment market is projected to grow at a CAGR of 8.3%
over the forecast period of 2019-2025.
Benign prostatic hyperplasia (BPH) is a medical condition
involving the expansion of the prostate gland and is highly prevalent in males.
It is a non-cancerous growth of the prostate gland originating from the
uncontrolled expansion of prostate cells. The common symptoms associated with
BPH include frequent urination, urine initiation difficulties, weak urinary
system, and inability to empty the urinary bladder.
The growing occurrence of benign prostatic hyperplasia coupled
with the growing risk factors are the major factors that drive the growth of
the benign prostatic hyperplasia treatment market across the globe.
Furthermore, the increase in the male geriatric population is the other key
factor that augments market growth. According to the United States Census Bureau
in 2018, the population of people aged 65 and above in the United States is
likely to increase drastically between 2016 and 2060. By 2030, one in five US
citizens is expected to be 65 years and older, crossing 78.0 million, out of
the total population. However, the high cost of benign prostatic hyperplasia
treatment is expected to may restrain the growth of the market. Moreover, the
growing preference for in-office based minimally invasive surgical techniques
creates an opportunity for the growth of the benign prostatic hyperplasia
treatment market in the next few years.
In terms of region, North America is expected to dominate the
benign prostatic hyperplasia treatment market during the forecast period. This
is attributed to factors such as the geriatric population, growing incidences
of benign prostatic hyperplasia, and highly structured healthcare industry in
the region. Furthermore, increasing the aging population of the United States
coupled with a rise in diabetes and obesity is poised to surge the occurrence
of benign prostatic hyperplasia and lower urinary tract conditions in the
region. Moreover, the Asia Pacific region is projected to grow at a faster rate
over the forecast period due to the high population base, growing disposable
income, and greater patient awareness about the benign prostatic hyperplasia
The report on the global benign prostatic hyperplasia treatment market
covers segments such as therapeutic class, therapy, and end user. On the basis
of therapeutic class, the sub-markets include alpha-blocker,
phosphodiesterase-5 inhibitor, 5-alpha reductase inhibitor, and other
therapeutic class. On the basis of therapy, the sub-markets include mono drug
therapy, and combination drug therapy. On the basis of end user, the
sub-markets include hospitals, specialty clinics, ambulatory surgical centers,
and other end users.
The report provides profiles of the companies in the market such
as Allergan plc, Eli Lilly and Company, Pfizer, Inc., Astellas Pharma, Inc.,
Abbott Laboratories, Boehringer Ingelheim GmbH, GlaxoSmithKline plc, Sanofi,
Merck & Co., Inc., and Teva Pharmaceutical Industries Ltd.
The report provides deep insights into the demand forecasts,
market trends, and micro and macro indicators. In addition, this report provides
insights into the factors that are driving and restraining the growth in this
market. Moreover, The IGR-Growth Matrix analysis given in the report brings an
insight into the investment areas that existing or new market players can
consider. The report provides insights into the market using analytical tools
such as Porter's five forces analysis and DRO analysis of benign prostatic
hyperplasia treatment market. Moreover, the study highlights current market
trends and provides forecast from 2019-2025. We also have highlighted future
trends in the market that will affect the demand during the forecast period.
Moreover, the competitive analysis given in each regional market brings an
insight into the market share of the leading players.